- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07265479
Een onderzoek naar de veiligheid en werkzaamheid van Tapinarofcrème, 1% bij deelnemers van 3 maanden tot < 24 maanden met constitutioneel eczeem (Adoring)
Een gerandomiseerde, dubbelblinde, voertuig-gecontroleerde (periode 1) en open-label (periode 2) fase 3-studie om de veiligheid en werkzaamheid van Tapinarof-crème, 1% te onderzoeken bij pediatrische deelnemers van 3 maanden tot < 24 maanden met atopische dermatitis
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alberta
-
Calgary, Alberta, Canada, T2J 7E1
- Dermatology Research Institute
-
Red Deer, Alberta, Canada, T4P 1K4
- CARe Clinic (Central Alberta Research Clinic)
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Dr. Chih-Ho Hong Medical Inc.
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3J 0S9
- Manitoba Allergy Research Inc.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 5R3
- Maritime Dermatology
-
-
Ontario
-
Burlington, Ontario, Canada, L7L 6W6
- Halton Pediatric Allergy
-
Hamilton, Ontario, Canada, L8S 1G5
- Triple A Lab Inc.
-
Niagara Falls, Ontario, Canada, L2H 1C4
- Allergy Research Canada Inc.
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4V 1R9
- Dr. Rachel Asiniwasis Medical Professional Corporation
-
Saskatoon, Saskatchewan, Canada, S7K 2C1
- Skinsense Medical Research
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35209
- AllerVie Clinical Research
-
-
Arkansas
-
Bryant, Arkansas, Verenigde Staten, 72022
- Dermatology Trial Associates
-
-
California
-
Los Angeles, California, Verenigde Staten, 90045
- Dermatology Research Associates
-
Sacramento, California, Verenigde Staten, 95815
- Integrative Skin Science and Research
-
San Diego, California, Verenigde Staten, 92123
- Allergy and Asthma Medical Group and Research Center
-
Thousand Oaks, California, Verenigde Staten, 91320
- Clinical Trials Research Institute
-
-
Colorado
-
Castle Rock, Colorado, Verenigde Staten, 80109
- Clarity Dermatology
-
-
Florida
-
Boca Raton, Florida, Verenigde Staten, 33486
- Skin Care Research, LLC.
-
Jacksonville, Florida, Verenigde Staten, 32256
- APEX Clinical Trials
-
Wellington, Florida, Verenigde Staten, 33449
- TruDerm Research
-
-
Georgia
-
Cumming, Georgia, Verenigde Staten, 30040
- Cleaver Medical Group Dermatology, Inc
-
-
Idaho
-
Meridian, Idaho, Verenigde Staten, 83646
- Ada West Research
-
-
Illinois
-
Skokie, Illinois, Verenigde Staten, 60077
- Endeavor Health Clinical Trials Center
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield, Indiana, Verenigde Staten, 46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Bowling Green, Kentucky, Verenigde Staten, 42104
- Equity Medical, LLC
-
-
Maryland
-
Rockville, Maryland, Verenigde Staten, 20850
- Lawrence J Green, MD LLC
-
-
Michigan
-
Auburn Hills, Michigan, Verenigde Staten, 48326
- Oakland Hills Dermatology
-
-
Minnesota
-
New Brighton, Minnesota, Verenigde Staten, 55112
- Minnesota Clinical Study Center
-
-
Mississippi
-
Ridgeland, Mississippi, Verenigde Staten, 39157
- SKY Integrative Medical Center
-
-
Missouri
-
Saint Joseph, Missouri, Verenigde Staten, 64506
- MediSearch Clinical Trials
-
-
Nevada
-
Reno, Nevada, Verenigde Staten, 89509
- Skin Cancer and Dermatology Institute
-
-
New York
-
Kew Gardens, New York, Verenigde Staten, 11415
- Forest Hills Dermatology Group
-
New York, New York, Verenigde Staten, 10012
- Bobby Buka MD, PC
-
The Bronx, New York, Verenigde Staten, 10455
- Equity Medical, LLC
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27516
- The University of North Carolina Dermatology and Skin Cancer Center
-
-
Ohio
-
Fairborn, Ohio, Verenigde Staten, 45324
- Dermatologists of Central States, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73120
- Allergy Asthma and Clinical Research Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Medical University of South Carolina
-
North Charleston, South Carolina, Verenigde Staten, 29420
- National Allergy and Asthma Research, LLC.
-
-
Texas
-
Bellaire, Texas, Verenigde Staten, 77401
- The University of Texas Health Science Center at Houston
-
Dallas, Texas, Verenigde Staten, 75230
- Dermatology Treatment and Research Center
-
Southlake, Texas, Verenigde Staten, 76092
- Stryde Research - Epiphany Dermatology
-
-
Washington
-
Spokane, Washington, Verenigde Staten, 99202
- Dermatology Specialists of Spokane
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Exclusion Criteria:
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Tapinarof cream
Tapinarof cream, 1%, applied topically once daily |
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
Andere namen:
|
|
Placebo-vergelijker: Vehicle cream
Vehicle cream is applied topically once daily for up to 8-weeks. |
Applied topically once daily to lesions on participant's skin during the Double-Blind period. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Tijdsspanne: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tijdsspanne: Baseline to the end of the Open-Label Period, up to 56 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tijdsspanne: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tijdsspanne: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tijdsspanne: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tijdsspanne: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Lead Late-Stage Clinical Development, Organon and Co
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Genetische ziekten, aangeboren
- Ziekten van het immuunsysteem
- Overgevoeligheid, Onmiddellijk
- Overgevoeligheid
- Huidziektes
- Huidziekten, genetisch
- Huidziekten, Eczeem
- Dermatitis
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Huid- en bindweefselaandoeningen
- Dermatitis, atopisch
- Eczeem
- tapinarof
Andere studie-ID-nummers
- OG0505-3104
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .